Member Exclusive

New treatment for genetic retinal disease is first gene therapy approved in the USA

LUXTURNA is the first pharmacologic treatment indicated for inherited retinal disease and the first adeno-associated virus vector gene therapy approved in the USA.

Go to the profile of RegMedNet
Dec 20, 2017

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.


No comments yet.